Dose Optimization for Novel Oncology Agents: Design Options and Strategies
- 26 February 2024
- journal article
- research article
- Published by Taylor & Francis in Statistics in Biopharmaceutical Research
- Vol. 16 (3) , 326-337
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- Cediranib With mFOLFOX6 Versus Bevacizumab With mFOLFOX6 As First-Line Treatment for Patients With Advanced Colorectal Cancer: A Double-Blind, Randomized Phase III Study (HORIZON III)Journal of Clinical Oncology, 2012
- Design Issues in Randomized Phase II/III TrialsJournal of Clinical Oncology, 2012
- Tumor Regression and Growth Rates Determined in Five Intramural NCI Prostate Cancer Trials: The Growth Rate Constant as an Indicator of Therapeutic EfficacyClinical Cancer Research, 2011
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Two‐Stage Designs for Dose‐Finding Trials with a Biologic Endpoint Using Stepwise TestsBiometrics, 2008
- An adaptive phase I design for identifying a biologically optimal dose for dual agent drug combinationsStatistics in Medicine, 2006
- Testing and estimation in flexible group sequential designs with adaptive treatment selectionStatistics in Medicine, 2005
- Combining Multiple Comparisons and Modeling Techniques in Dose‐Response StudiesBiometrics, 2005
- Dose‐Finding Based on Efficacy–Toxicity Trade‐OffsBiometrics, 2004
- An improved Bonferroni procedure for multiple tests of significanceBiometrika, 1986